Navigation Links
Cancer Experts Meet in Boston to Discuss a Promising Approach to Treating the Disease
Date:10/21/2013

CAMBRIDGE, Mass., Oct. 21, 2013 /PRNewswire/ -- Academics, healthcare providers, and pharmaceutical industry professionals are gathered in Boston to discuss the latest advances in cancer research. The evening of Tuesday, October 22, those professionals are invited to attend a symposium that will explore one of the most exciting targets in cancer treatment, a protein called hypoxia-inducible factor-1a, or HIF-1a.

The role of HIF-1a in solid tumors has been well documented. It is often present in solid tumors where hypoxic, or low oxygen, conditions are common, and its presence may be increased by anti-angiogenic medicines and radiation. Because HIF-1a can promote resistance, leaders in government, academia, and industry have long sought an effective HIF-1a inhibitor. This week, experts will discuss whether the potential of HIF-1a inhibition is soon to become a reality.

The pre-clinical panel features Giovanni Melillo, MD, of AstraZeneca and formerly of the National Cancer Institute; Sarah Conley, PhD, of MedImmune and formerly of the Max Wicha Lab at the University of Michigan; Amato Giaccia, PhD, of Stanford University; and Robert Kerbel, PhD, of the University of Toronto.

The clinical panel features William Kaelin, MD, of Harvard Medical School; Laura Benjamin, PhD, of Eli Lilly; Mark Dewhirst, DVM, PhD, of Duke University School of Medicine; and Steve Keefe, MD, of the Abramson Cancer Center at the University of Pennsylvania.

Oliver Fetzer, PhD, President and CEO of symposium sponsor, Cerulean Pharma, will welcome attendees, and Robert A. Weinberg, PhD, of the Massachusetts Institute of Technology, will provide closing remarks. WHO: Academics, professionals, and journalists interested in the latest research on the HIF-1a protein and the advances that illustrate its value as a target for new medicinesWHAT: HIF-1a: Ready for Prime Time? includes pre-clinical and clinical panels, closing remarks, a poster exhibition, and a dinner receptionWHEN: Tuesday, October 22, 2013, from 5:30 p.m. to 9:30 p.m.WHERE: Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115REGISTER: Online at www.HIFSymposium.com, via email at register@hospicom.us with "HIF Symposium" in the subject line, or by phone at 845-265-2155 specifying "HIF Symposium"; please note institution, degree, and phone number when registering; there is no fee 

Media Contact: 
Laura Kempke or Kristin Villiotte 
Schwartz MSL 
cerulean@schwartzmsl.com 
+1 781-684-0770


'/>"/>
SOURCE Cerulean Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
3. Nucletron, an Elekta Company, Receives U.S. FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
4. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
5. Sedationless Colonoscopy Option May Increase Colorectal Cancer Screening Compliance
6. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
7. First urine-based cancer mutation monitoring test available from Trovagene
8. Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
9. Varians Calypso Tumor Tracking System Used in Lung, Stomach and Prostate Cancer Treatments at Leading European Cancer Center
10. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
11. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 ... new market research report "Fetal (Labor & Delivery) and ... Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, ... by MarketsandMarkets, This report studies the global market over ... is estimated at USD 6.28 Billion in 2015 and ...
(Date:2/4/2016)... 2016 For hospitals considering enrollment in the ... in the program, the Health Resources and Services Administration,s ... , Mega-Guidance , could have significant impact on plans ... September 2016. Essential Insights , Daniel ... summarizes the Mega-Guidance,s key proposed changes, including a new ...
(Date:2/4/2016)... FOSTER CITY, Calif. , Feb. 4, 2016 ... (the "Company") today announced it has entered into ... and Exchange Commission (SEC) fully resolving the SEC,s ... Practices Act (FCPA).  Under the terms of the ... total of $12.8 million, including disgorgement, pre-judgment interest ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... Regular ... and find themselves having to wait longer to access the treadmills. It’s a predictable ... Year’s resolutions to lose weight and get in shape by joining gyms, starting new ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Boar’s Head ... just in time for this weekend’s Big Game. Take the stress out of your ... will keep your guests happy at every stage of the game. , “The key ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Stuart Bentkover, ... technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover ... unmatched results. , Developed by Cynosure, the PicoSure has been approved by the Food ...
Breaking Medicine News(10 mins):